Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Stock-Based Compensation

The Stock-Based Compensation (SBC) of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 17, 2026 is 5.78 M CNY. In the previous year, Stock-Based Compensation (SBC) was 11.65 M CNY — a change of -50.40% (lower).

Stock-Based Compensation

5.78 MCNY

YoY

-50.40%

Last updated:

Stock-Based Compensation (SBC) of Vcanbio Cell & Gene Engineering Corp is 2015 5.78 M CNY. Stock-Based Compensation (SBC) of Vcanbio Cell & Gene Engineering Corp was 2014 11.65 M CNY. It decreases by -50.40% lower compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2014
11.65 M CNY
Jan 1, 2015
5.78 M CNY
The Vcanbio Cell & Gene Engineering Corp Stock-Based Compensation history
YEARStock-Based CompensationYoY
5.78 MCNY-50.40%
11.65 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp Ltd is a biotechnology company based in Tianjin, China, operating within the healthcare sector. The company has been publicly traded since its IPO on May 4, 1993, and is listed under the ticker 600645.SS with ISIN CNE000000545. It employs 2,332 full-time staff and focuses on the development of life sciences technology. Vcanbio engages in cell culture, gene detection, and storage services, as well as the production and sale of cytokines culture solutions, cosmetics, and detection reagents. The company primarily serves domestic markets in China, with its headquarters located in Tianjin. Its website is http://www.vcanbio.com. The firm's business activities include the development and application of biotechnology solutions, though specific details on product names, acquisitions, or additional financial figures are not provided in the available information. Vcanbio operates as a public company with a presence in the Chinese biotechnology industry, emphasizing innovation in cell and gene engineering. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Stock-Based Compensation (SBC) of Vcanbio Cell & Gene Engineering Corp is 5.78 M CNY in 2015.

Stock-Based Compensation (SBC) of Vcanbio Cell & Gene Engineering Corp changed from 11.65 M CNY to 5.78 M CNY, representing a -50.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Vcanbio Cell & Gene Engineering Corp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Vcanbio Cell & Gene Engineering Corp

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Vcanbio Cell & Gene Engineering Corp